Literature DB >> 16103760

Pharmacotherapy review: angiotensin-converting enzyme inhibitors.

Domenic A Sica1.   

Abstract

On inspection of most treatment algorithms for hypertension, it is apparent that multiple drug classes are available. In choosing a medication class for hypertension therapy, nuances of the selection process often go unappreciated. This article is the first in a series describing important pharmacotherapeutic considerations of the individual drug classes used in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103760      PMCID: PMC8109375          DOI: 10.1111/j.1524-6175.2005.04125.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  28 in total

1.  Overlap between whites and blacks in response to antihypertensive drugs.

Authors:  Ashwini R Sehgal
Journal:  Hypertension       Date:  2004-02-02       Impact factor: 10.190

2.  The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.

Authors:  H R Black; J S Sollins; J L Garofalo
Journal:  Am J Hypertens       Date:  2000-05       Impact factor: 2.689

3.  Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group.

Authors:  V DeQuattro; D Lee
Journal:  Am J Hypertens       Date:  1997-07       Impact factor: 2.689

4.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

Authors:  Lindon M H Wing; Christopher M Reid; Philip Ryan; Lawrence J Beilin; Mark A Brown; Garry L R Jennings; Colin I Johnston; John J McNeil; Graham J Macdonald; John E Marley; Trefor O Morgan; Malcolm J West
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

Review 5.  Pharmacogenomics of blood pressure response to antihypertensive treatment.

Authors:  Philip B Mellen; David M Herrington
Journal:  J Hypertens       Date:  2005-07       Impact factor: 4.844

6.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

7.  Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial.

Authors:  Evan Mokwe; Suzanne E Ohmit; Samar A Nasser; Tariq Shafi; Elijah Saunders; Errol Crook; Amanda Dudley; John M Flack
Journal:  Hypertension       Date:  2004-04-26       Impact factor: 10.190

Review 8.  Treatment of hypertensive patients with coexisting coronary arterial disease.

Authors:  Andrew Docherty; Francis G Dunn
Journal:  Curr Opin Cardiol       Date:  2003-07       Impact factor: 2.161

9.  The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.

Authors:  Nadia A Khan; Finlay A McAlister; Norman R C Campbell; Ross D Feldman; Simon Rabkin; Jeff Mahon; Richard Lewanczuk; Kelly B Zarnke; Brenda Hemmelgarn; Marcel Lebel; Mitchell Levine; Carol Herbert
Journal:  Can J Cardiol       Date:  2004-01       Impact factor: 5.223

10.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

Authors:  M R Law; N J Wald; J K Morris; R E Jordan
Journal:  BMJ       Date:  2003-06-28
View more
  1 in total

Review 1.  Protease pathways in peptide neurotransmission and neurodegenerative diseases.

Authors:  Vivian Y H Hook
Journal:  Cell Mol Neurobiol       Date:  2006-05-25       Impact factor: 5.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.